Precision Cancer Therapies Market Size, Status and Forecast 2025 Trends, Size, Drivers, Strategies, Products and – The Market Stats News

Precision Cancer Therapies Market research now available at Brand Essence Research encompasses an exhaustive Study of this business space with regards to pivotal industry drivers, market share analysis, and the latest trends characterizing the Precision Cancer Therapies industry landscape. This report also covers details of market size, growth spectrum, and the competitive scenario of Precision Cancer Therapies market in the forecast timeline.

The Precision Cancer Therapies Market Report provides key strategies followed by leading Precision Cancer Therapies industry manufactures and Sections of Market like- product specifications, volume, production value, Feasibility Analysis, Classification based on types and end user application areas with geographic growth and upcoming advancement. The Precision Cancer Therapies market report provides comprehensive outline of Invention, Industry Requirement, technology and production analysis considering major factors such as Revenue, investments and business growth.

Request for Sample of this Report@ https://brandessenceresearch.biz/Request/Sample?ResearchPostId=97705&RequestType=Sample

The well-established players in the market are:

Abbott Laboratories, Bayer HealthCare, GlaxoSmithKline, OncoGenex Pharmaceuticals, Hospira, Boehringer Ingelheim, AstraZeneca, Aveo Pharmaceuticals

This report for Precision Cancer Therapies Market discovers diverse topics such as regional market scope, product market various applications, market size according to specific product, sales and revenue by region, manufacturing cost analysis, Industrial Chain, Market Effect Factors Analysis, market size forecast, and more.

Drivers & Hindrances of the Precision Cancer Therapies market: How does the report explicate on the same

The report unveils the driving parameters affecting the commercialization chart of this industry.

The Precision Cancer Therapies market research report further illustrates the various challenges that this market is prone to as well as its impact on the market trends.

An important aspect that the report sets focus on is the market concentration ratio for the predicted timeframe.

Important Points Mentioned In the Precision Cancer Therapies Market

Manufacturing Analysis:The report comprises descriptive information after analyzing multiple segments of Precision Cancer Therapies market, which include product type and applications, among others. Precision Cancer Therapies market report includes a separate chapter emphasizing thorough analysis of the manufacturing process authenticated via primary information gathered from key officials of reputed industries and several industry analysts.

Sales and Revenue Estimation:By implementing several top-down and bottom-up approaches on the historical sales & revenue data and the current market status, the researchers have forecasted the market growth and size in key regions. Moreover, the report includes a comprehensive study on classified and prominent types as well as end-use industry. The report even provides significant information related to regulatory policies and macroeconomic factors that determine Precision Cancer Therapies industry evolution and predictive analysis.

Demand & Supply Assessment:Precision Cancer Therapies report also offers important information on product & service distribution, manufacturing, Consumption, and Export & Import (EXIM) ** if applicable.

Competitiveness:Precision Cancer Therapies report provides key information based on the product portfolio, company profile, product & service cost, potential, and sales & revenue generated by the global and regional leading companies.

Market segment by Type, the product can be split into

Hormone Therapy, Immunotherapies, Targeted Therapy, Monoclonal Antibody Therapy, Gene Therapy

Market segment by Application, split into

Hospitals, Diagnostic Centers, Oncology Clinics, Research Institutes

Market segment by Regions/Countries, this report covers

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia and Turkey etc.)

Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)

South America (Brazil etc.)

Middle East and Africa (Egypt and GCC Countries)

Request Customization of this Report: https://brandessenceresearch.biz/Request/Sample?ResearchPostId=97705&RequestType=Customization

Key highlights and essential features of the report:

1) Which major players are presently listed in the report?Here are the companies that are presently listed in the report: Abbott Laboratories, Bayer HealthCare, GlaxoSmithKline, OncoGenex Pharmaceuticals, Hospira, Boehringer Ingelheim, AstraZeneca, Aveo Pharmaceuticals

**List of the firms stated above might differ in the final report dependent on a merger, name change, and other factors.

2) Can you list or add new firms as per our requirement?Yes,we can list or add new firm as per the requirement by client in the report. The final confirmation regarding the same must be provided by the research team subject to difficulty of survey.

**Availability of data will be confirmed after research in case of a privately held firm. Maximum 3 companies can be included at no additional charge.

3) Which all regional categorization are covered? Is it possible to add any specific country?Presently, our research report offers special focus and attention on the following areas:Europe, United States, Japan, China, India, Southeast Asia, and Central & South America

**Maximum one country of specific interest can be added at no extra charge. Charges will be applied for the addition of extra countries or regions.

4) Can the addition of extra Market breakdown or segmentation is possible?Yes, the addition of extra Market breakdown or segmentation is possibly dependent on the difficulty of survey and availability of data. On the other hand, detailed sharing of the requirements with our research team is a must before providing final confirmation to the client.

More Details on this Report: https://brandessenceresearch.biz/Medical-Devices-and-Consumables/Global-Precision-Cancer-Therapies-Industry-Market-Research-2019/Summary

There are 15 Chapters to display the Global Precision Cancer Therapies market

Chapter 1, Definition, Specifications and Classification of Precision Cancer Therapies , Applications of Precision Cancer Therapies , Market Segment by Regions;

Chapter 2, Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;

Chapter 3, Technical Data and Manufacturing Plants Analysis of Precision Cancer Therapies , Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;

Chapter 4, Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);

Chapter 5 and 6, Regional Market Analysis that includes United States, China, Europe, Japan, Korea & Taiwan, Precision Cancer Therapies Segment Market Analysis (by Type);

Chapter 7 and 8, The Precision Cancer Therapies Segment Market Analysis (by Application) Major Manufacturers Analysis of Precision Cancer Therapies ;

Chapter 9, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;

Chapter 10, The Consumers Analysis of Global Precision Cancer Therapies ;

Chapter 11, Precision Cancer Therapies Research Findings and Conclusion, Appendix, methodology and data source;

Chapter 12, 13 and 14, Precision Cancer Therapies sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Read More Report:

https://www.marketwatch.com/press-release/intelligent-motor-controller-market-2019-industry-analysis-share-trends-opportunities-strategies-and-forecasts-2025-2019-12-02

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Contact US:

https://brandessenceresearch.biz/

Brandessence Market Research & Consulting Pvt ltd.

Kemp House, 152 160 City Road, London EC1V 2NX

+44-2038074155

sales@brandessenceresearch.com

See the rest here:
Precision Cancer Therapies Market Size, Status and Forecast 2025 Trends, Size, Drivers, Strategies, Products and - The Market Stats News

Jasper Therapeutics Launches with $35 Million Series A Financing to Develop and Commercialize Innovative Conditioning Agents and Therapies to…

PALO ALTO, Calif.--(BUSINESS WIRE)-- Jasper Therapeutics, Inc., a new biotechnology company focused on enabling safer conditioning and therapeutic agents that expand the application of curative hematopoietic stem cell transplants and gene therapies, today announced the launch of the company with a $35 million total Series A financing. Abingworth LLP and Qiming Venture Partners USA served as lead investors, with further investment from Surveyor Capital (a Citadel company) and participation from Alexandria Venture Investments, LLC. The proceeds will be used to advance the clinical development of the companys lead product candidate, JSP191, which is designed to replace or reduce the toxicity of chemotherapy and radiation therapy as a conditioning regimen to prepare patients for hematopoietic cell transplant.

Jaspers development of JSP191 is also supported by a collaboration with the California Institute for Regenerative Medicine (CIRM), which has been funding the program and is committed to providing a total of $23 million in grant support. As part of the Series A financing, Amgen, which discovered JSP191 (formerly AMG191), has licensed worldwide rights to Jasper that also include translational science and materials from Stanford University.

Jasper was co-founded by Judith Shizuru, M.D., Ph.D., a hematopoietic stem cell transplant expert at Stanford University, and Susan Prohaska, Ph.D., a Stanford University-trained immunologist, stem cell biologist and early-stage drug development professional. Dr Shizurus CIRM-funded lab advanced the understanding of the ability of anti-CD117 to impact hematopoietic stem cells and, together with the Lucile Packard Childrens Hospital Stanford and University of California, San Francisco (UCSF) pediatric transplant teams, was the first to study an anti-CD117 antibody in the clinic as a conditioning agent. That humanized antibody, now called JSP191, was first studied for conditioning for transplant in immune-deficient patients in collaboration with Amgen, UCSF and CIRM.

Stem cell transplantation is a potential curative therapy for people with hematologic cancers, autoimmune diseases, and debilitating genetic diseases. However, the pre-transplant conditioning required to prepare patients for transplant involves highly toxic chemotherapy, which can be life-threatening and limits the number of people who are able to benefit, said Dr. Shizuru, co-founder and member of the Board of Directors of Jasper Therapeutics. JSP191 is the only anti-CD117 antibody to demonstrate safety and efficacy in severely ill patients receiving stem cell transplant in the clinic. We plan to expand clinical development to patients receiving transplants for acute myeloid leukemia/ myelodysplastic syndrome or autoimmune diseases and to patients receiving stem cell-directed gene therapies.

Dr. Shizuru added, With an experienced executive team of biotech veterans and a strong syndicate of healthcare-focused investors, Jasper Therapeutics is well positioned to achieve our vision of building a leading biotech company starting with JSP191 and expanding to other novel therapies for immune modulation, graft engineering and cell and gene therapies.

JSP191 is currently being evaluated in an ongoing Phase 1 clinical trial as a conditioning agent to enable stem cell transplantation in patients with severe combined immunodeficiency (SCID) who received a prior stem cell transplant that failed. This severe genetic immune disorder leaves patients without a functioning immune system. Interim results of the study will be presented in an oral presentation (abstract #800) on Monday, December 9, at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Fla. Clinical studies to evaluate the safety and efficacy of JSP191 as a conditioning agent in patients undergoing hematopoietic cell therapy for hematologic cancers are planned for 2020.

Founding Management Team

Dr. Shizuru and Mr. Lis are joined on the Jasper Therapeutics Board of Directors by Kurt von Emster, Managing Partner of Abingworth LLP, and Anna French, Ph.D., Principal at Qiming Venture Partners USA. Dr. Prohaska is a Board observer.

With our investment in this program, were able to realize our mission of fast-tracking stem cell treatments by helping academic researchers rapidly advance the most promising discoveries in the lab into the clinics and to drug development with commercialization partners, said Maria T. Millan, M.D., President and CEO of CIRM. Jaspers two co-founders took a novel antibody with unique properties and moved it from the bench to the bedside relatively quickly, and were thrilled to partner with this talented team to potentially impact a broad group of people who could benefit from stem cell therapy.

About Stem Cell Transplantation

Blood-forming, or hematopoietic, stem cells are cells that reside in the bone marrow and are responsible for the generation and maintenance of all blood and immune cells. These stem cells can harbor inherited or acquired abnormalities that lead to a variety of disease states, including immune deficiencies, blood disorders or hematologic cancers. Successful transplantation of hematopoietic stem cells is the only cure for most of these life-threatening conditions. Replacement of the defective or malignant hematopoietic stem cells in the patients bone marrow is currently achieved by subjecting patients to toxic doses of radiation and/or chemotherapy that cause DNA damage and lead to short- and long-term toxicities, including immune suppression and prolonged hospitalization. As a result, many patients who could benefit from a stem cell transplant are not eligible. New approaches that are effective but have minimal to no toxicity are urgently needed so more patients who could benefit from a curative stem cell transplant could receive the procedure.

Safer and more effective hematopoietic cell transplantation regimens could overcome these limitations and enable the broader application of hematopoietic cell transplants in the cure of many disorders. These disorders include hematologic cancers (e.g., myelodysplastic syndrome [MDS] and acute myeloid leukemia [AML]), autoimmune diseases (e.g., lupus, rheumatoid arthritis, multiple sclerosis and Type 1 diabetes), and genetic diseases that could be cured with genetically-corrected autologous stem cells (e.g., severe combined immunodeficiency syndrome [SCID], sickle cell disease, beta thalassemia, Fanconi anemia and other monogenic diseases).

About JSP191

JSP191 (formerly AMG191) is a first-in-class humanized monoclonal antibody in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow. JSP191 binds to human CD117, a receptor for stem cell factor (SCF) that is expressed on the surface of hematopoietic stem and progenitor cells. The interaction of SCF and CD117 is required for stem cells to survive. JSP191 blocks SCF from binding to CD117 and disrupts critical survival signals, causing the stem cells to undergo cell death and creating an empty space in the bone marrow for donor or gene-corrected transplanted cells to engraft.

Preclinical studies have shown that JSP191 as a single agent safely depletes normal and diseased hematopoietic stem cells, including in an animal model of MDS. This creates the space needed for transplanted normal donor or gene-corrected hematopoietic stem cells to successfully engraft in the host bone marrow. To date, JSP191 has been evaluated in more than 80 healthy volunteers and patients. It is currently being evaluated as a sole conditioning agent in a Phase 1 dose-escalation trial to achieve donor stem cell engraftment in patients undergoing hematopoietic cell transplant for SCID, which is curable only by this type of treatment. For more information about the design of the clinical trial, visit http://www.clinicaltrials.gov (NCT02963064). Clinical development of JSP191 will be expanded to also study patients with AML or MDS who are receiving hematopoietic cell transplant.

About Jasper Therapeutics

Jasper Therapeutics is a biotechnology company focused on enabling safer conditioning and therapeutic agents that expand the application of curative hematopoietic stem cell transplants and gene therapies. Jasper Therapeutics lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem cell transplant. For more information, please visit us at http://www.jaspertherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191206005456/en/

Continued here:
Jasper Therapeutics Launches with $35 Million Series A Financing to Develop and Commercialize Innovative Conditioning Agents and Therapies to...

ASH to Highlight Advances, Science Behind Them – MedPage Today

ORLANDO -- Science and data that have fueled the rapidly evolving field of hematology figure prominently in the program for the 2019 American Society of Hematology (ASH) meeting, which begins here today.

The largest hematology conference in the world, ASH will host more than 25,000 attendees from 115 countries. The program includes almost 5,000 research abstracts, 1,000 of which were selected for presentation at oral sessions.

"This really is just a great, grand meeting of the minds," said chair of the ASH communications committee, Aaron Gerds, MD, of the Cleveland Clinic.

The meeting begins with a day of continuing education programming, covering all aspects of hematology. Industry-sponsored satellite symposia feature some of the leaders in their respective fields, offering insights into key clinical issues and ongoing research and development. Afternoon scientific workshops introduce attendees to current science and emerging scientific concepts that will provide the basis for future clinical advances.

Abstract presentations begin early Saturday and continue through mid-day Tuesday.

Developments in the field of CAR T-cell therapy will continue to figure prominently in the key scientific presentations.

"CAR T-cells have captured the imagination of physicians, scientists, and patients, mainly for their incredible efficacy in treating B-cell malignancies," said ASH secretary Robert Brodsky, MD, of Johns Hopkins School of Medicine in Baltimore. "But there have been a number of drawbacks. One is the time and expense required to generate patient-specific CAR T cells. Only about two thirds of patients enrolled in clinical trials of CAR T cells will actually receive the treatment, as many times the disease will progress during the time it takes to produce the cells. Toxicity has been another issue."

Several abstracts at ASH will feature strategies to overcome some of the limitations of CAR T-cell therapy. Examples of the research that will be presented include an off-the-shelf CAR NK cell for B-cell malignancies, clinical data from a trial of CAR T-cell therapy directed against B-cell maturation antigen (BCMA) in relapsed/refractory multiple myeloma, and a bispecific CAR T cell therapy targeting BCMA and CD38 in relapsed/refractory myeloma.

The Presidential Plenary Session will include data on mosunetuzumab, a monoclonal antibody that has induced complete remission in patients with poor-prognosis non-Hodgkin's lymphoma that is resistant to or has relapsed after CAR T-cell therapy. A high response rate and persistence were observed in a difficult-to-treat population, including patients whose disease was refractory to CAR T-cell therapy, said Brodsky.

In the area of venous thromboembolism (VTE), the program includes several potentially practice-changing studies, said ASH president Roy Silverstein, MD, of Medical College of Wisconsin in Milwaukee. A trial of an oral formulation of rivaroxaban for VTE prevention in children demonstrated equivalent efficacy with low molecular weight heparin. The oral formulation facilitated administration and acceptance and will likely become a new standard of care for children with VTE, said Silverstein.

Another study evaluated the common practice of adding aspirin without an apparent indication to a direct oral anticoagulant (DOAC) for patients with atrial fibrillation or VTE. The results showed similar rates of recurrent thrombosis or stroke in patients who received DOACs alone or with aspirin, but aspirin-treated patients had more clinically relevant, nonmajor bleeding events.

"This is an example of less is more," said Silverstein. "It will provide good evidence to our community practitioners that when starting a DOAC for nonvalvular atrial fibrillation or venous thrombosis, patients should not also receive aspirin unless there is a clear indication, such as a recent stenting or coronary disease."

A number of sessions will address the issue of inclusiveness in medicine. Examples include a comprehensive evaluation of data on stem-cell transplantation for multiple myeloma, showing that older and younger patients derive similar benefit. Older patients who did worse tended to receive less-than-optimal dosing of melphalan, a pretransplant conditioner.

"The results suggest we are under-referring patients for bone marrow transplant on the basis of age alone and perhaps undertreating the ones who are referred," said Silverstein. "This is a very important abstract that gets to the point that age as a number is probably not adequate as an exclusion or inclusion in clinical trials."

A study of "real-world" experience with CAR T-cell therapy showed that older patients did well on the therapy and had a lower rate of healthcare resource utilization.

The late-breaking abstract session on Tuesday will include an entire lineup of potentially practice-changing studies, said Brodsky. The studies include a randomized phase III trial showing the superiority of blinatumomab (Blincyto) versus chemotherapy as post-induction therapy for children, adolescents, and young adults in first relapse of B-acute lymphoblastic leukemia; inhibition of C1s with monoclonal antibody sutimlimab in patients with cold agglutinin disease; a randomized, placebo-controlled phase III trial of an oral formulation of azacitidine for patients with acute myeloid leukemia in first remission; and a randomized trial demonstrating the superiority of adding daratumumab (Darzalex) to carfilzomib (Kyprolis) and dexamethasone versus carfilzomib and dexamethasone in relapsed/refractory myeloma.

The 2019 ASH meeting will continue until Tuesday afternoon.

2019-12-06T17:08:27-0500

Read more here:
ASH to Highlight Advances, Science Behind Them - MedPage Today

One of Wall Street’s most high-profile hedge funds pushes Alexion’s CEO to the auction block and he’s not budging – Endpoints News

Exhilarating. A major advance. A milestone achievement. If one had just tuned into the panel comments on Biogens presentation at CTAD, it would seem that the biotech had an impressive, disease-modifying Alzheimers drug in aducanumab.

But off the stage, reactions to their admittedly complicated dataset and the biotechs explanation for resurrecting a drug that failed its futility analysis were a lot more mixed, with analysts continuing to question whether the evidence is substantial enough to warrant an FDA approval and raising new doubts on the safety side.

In an investor call later in the day, execs noted that they are not planning another study and stood by their intention, publicized in October to much surprise, to submit regulatory filings based on what they have.

We dont file willy nilly, said Al Sandrock, head of R&D. We only go to filing when we believe that there is a benefit-risk argument based on science, based on data. And if you look at our history, we havent done filings right and left without good reason.

Biogen had a theory going into the Clinical Trials on Alzheimers Disease meeting.

Unlock this story instantly and join 67,000+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

Continue reading here:
One of Wall Street's most high-profile hedge funds pushes Alexion's CEO to the auction block and he's not budging - Endpoints News

Orgenesis and Theracell to launch point-of-care cell and gene therapy centers in HYGEIA Group"s hospitals – Proactive Investors USA & Canada

CEO Vered Caplan says the move would enable the development and delivery of cell and gene therapies onsite at HYGEIA's hospitals in Greece

Inc (), a developer of advanced cell therapies, revealed Friday that it struck a strategic partnership agreement between the Theracell joint venture and the large HYGEIA Group which runs three hospitals in Greece.

In a statement, the Germantown, Maryland-based company said that under the terms of the agreement, the joint venture will implement point-of-care cell therapy platform for clinical development and commercialization of cell and gene therapies within the HYGEIA Groups network of hospitals in Greece.

and TheraCell Advanced Biotechnology earlier formed a joint venture to advance point-of-care platform in Greece, the Balkan region and some Middle Eastern countries.

The point-of-care platform is designed to collect, process and supply cells within the patient care setting for various treatments.

The main goal is to reduce the cost and complexity of supplying cell and gene therapies, said , as well as boostquality by integrating automated processing units and proprietary technologies.

Significantly, HYGEIA is the first hospital network in the region to implement Orgenesis point-of-care cell therapy platform. The partnership aims to provide the HYGEIA Group with resources to advance clinical development and deliver personalized, advanced therapies across its network for a range of diseases in oncology, hematology, orthopedics, nephrology, dermatology and diabetes.

This partnership with the HYGEIA Group further validates the significant value proposition of our point-of-care platform, as it enables the development and delivery of cell and gene therapies onsite at hospitals, said Orgenesis CEO Vered Caplan.

We believe this platform has the potential to transform the cell and gene therapy market, by bringing life-saving therapies to market in a much more time and cost-effective manner, she added.

The Orgenesis boss said Theracell had proved to be an ideal partner with extensive experience and capabilities in autologous cell therapy and regenerative medicine, and strong operations in Greece and relationships in the region.

We are in active discussions to establish PoCare locations and partnerships with hospitals and healthcare networks in other countries and regions across the world, said Caplan.

Greeces HYGEIA Group operates three hospitals with a capacity of 1,261 beds, 52 operating rooms, 19 delivery rooms and 10 intensive care units.

HYGEIA Group CEO Andreas Kartapanis said thanks to the partnership with Theracell and Orgenesis it would be the first hospital network in Greece to provide advanced cell and gene therapies.

We believe this partnership will provide us a strong competitive advantage in this rapidly developing field. More importantly, this partnership will benefit patients that will now have greater access to these important therapies, said Kartapanis.

For the fiscal third quarter ended September 30, Orgenesis generated meaningful revenue, over $1 million, through its rapidly advancing point-of-care cellular therapy platform.

Meanwhile, TheraCell has experience in the isolation, processing and application of adipose-derived stem cells, as well as somatic cells. It has developed a patented platform for tissue engineering and cell therapies in the areas of dermatology, articular cartilage defects, and chronic kidney injury.

Contact Uttara Choudhury at[emailprotected]

Follow her onTwitter:@UttaraProactive

Read more:
Orgenesis and Theracell to launch point-of-care cell and gene therapy centers in HYGEIA Group"s hospitals - Proactive Investors USA & Canada

Stem Cell Therapy Industry 2019 Global Market Size, Trends, Revenue, Growth Prospects, Key Companies and Forecast by 2023 – Techi Labs

Bone marrow transplant is the most widely used stem-cell therapy, but some therapies derived from umbilical cord blood are also in use. Research is underway to develop various sources for stem cells, and to apply stem-cell treatments for neurodegenerative diseases and conditions, diabetes, heart disease, and other conditions.

With the ability of scientists to isolate and culture embryonic stem cells, and with scientists growing ability to create stem cells using somatic cell nuclear transfer and techniques to create induced pluripotent stem cells, controversy has crept in, both related to abortion politics and to human cloning. Additionally, efforts to market treatments based on transplant of stored umbilical cord blood have been controversial.

Click to Access Sample Pages @https://www.orianresearch.com/request-sample/609805

Scope of the Report:

This report studies the Stem Cell Therapy market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Stem Cell Therapy market by product type and applications/end industries.

USA is a huge market, and the total sum of the industry is more than 24 Million US dollars in 2014. At the same time, this industry continuously increases, with the development of global economy.

According to the research, the most potential market in the main countries of stem cell therapy industry is China, determined by the rising level of medical care. Besides, South America, Middle East should also be focused by the investors. They are the potential consumers of stem cell therapy.

Complete report on Stem Cell Therapy Market report spread across 139 pages, profiling 18 companies and supported with tables and figures.

Inquire more or share questions if any before the purchase on this report @https://www.orianresearch.com/enquiry-before-buying/609805

Development policiesand plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. The report focuses on global major leading Stem Cell Therapy Industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The Stem Cell Therapy industry development trends and marketing channels are

Analysis ofStem Cell Therapy Industry Key Manufacturers:

Order a Copy of Global Stem Cell Therapy Market Report @https://www.orianresearch.com/checkout/609805

This report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering:

Market Segment by Type, covers

Market Segment by Applications, can be divided into

Table of Contents

There are 15 Chapters to deeply display the global Banknote-Printing Machine market.

Chapter 1, to describe Banknote-Printing Machine Introduction, product scope, market overview, market opportunities, market risk, market driving force

Chapter 2, to analyze the top manufacturers of Banknote-Printing Machine, with sales, revenue, and price of Banknote-Printing Machine, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Banknote-Printing Machine, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Banknote-Printing Machine market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Banknote-Printing Machine sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Customization Service of the Report:Orian Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About Us:

Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Visit link:
Stem Cell Therapy Industry 2019 Global Market Size, Trends, Revenue, Growth Prospects, Key Companies and Forecast by 2023 - Techi Labs

Rocket Pharmaceuticals Announces First Patient Treated in Global Registrational Phase 2 Study of RP-L102 Process B for Fanconi Anemia – BioSpace

NEW YORK--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that the first patient in the global Phase 2 registration-enabling study of RP-L102 Process B received investigational therapy. RP-L102 is the Companys lentiviral vector (LVV)-based gene therapy for the treatment of Fanconi Anemia (FA).

The initiation of Rockets first Phase 2 trial is an important milestone for the company as well as patients throughout the world battling FA, said Kinnari Patel, Pharm.D., MBA, Chief Operating Officer and Head of Development of Rocket. With the recent feedback received from the FDA and EMA of MMC-resistance as the primary endpoint, we are optimistic about the prospect of benefiting patients and, if the data are positive, working towards BLA and MAA submissions.

The registrational package will include twelve patients from the U.S. and EU, two from the U.S. Phase 1 study and 10 additional patients from the global Phase 2 study (NCT04069533). Patients will receive a single intravenous infusion of RP-L102 that utilizes fresh cells and Process B which incorporates a modified stem cell enrichment process, transduction enhancers, as well as commercial-grade vector and final drug product. Improved mitomycin-C (MMC) resistance in bone marrow colony forming (progenitor) cells is the primary endpoint, and may also serve as a surrogate endpoint for accelerated approval. Additional outcome measures include stability or increase in blood counts with no significant worsening in anemia, neutropenia or thrombocytopenia and peripheral blood and bone marrow genetic correction, as demonstrated by progressive increases in vector copy number (VCN) over the months subsequent to infusion.

Lucile Packard Childrens Hospital Stanford and Hospital Infantil Universitario Nio Jess are serving as the lead clinical sites and University of Minnesota is conducting centralized evaluation of bone marrow MMC-resistance and engaging in advisory activities for the global trial of RP-L102. RP-L102 was in-licensed from the Centro de Investigaciones Energticas, Medioambientales y Tecnolgicas (CIEMAT), Centro de Investigacin Biomdica en Red de Enfermedades Raras (CIBERER), Instituto de Investigacin Sanitaria Fundacin Jimnez Daz (IIS-FJD) and Fundacion para la Investigacion Biomedica Hospital Infantil Universitario Nio Jesus (FIB-HIUNJ).

About Fanconi Anemia

Fanconi Anemia (FA) is a rare pediatric disease characterized by bone marrow failure, malformations and cancer predisposition. The primary cause of death among patients with FA is bone marrow failure, which typically occurs during the first decade of life. Allogeneic hematopoietic stem cell transplantation (HSCT), when available, corrects the hematologic component of FA, but requires myeloablative conditioning, which is highly toxic for the patient. HSCT is frequently complicated by graft versus host disease and also increases the risk of solid tumors, particularly upper aerodigestive tract squamous cell carcinomas. Approximately 60-70% of patients with FA have a FANCA gene mutation, which encodes for a protein essential for DNA repair. Mutations in the FANCA gene leads to chromosomal breakage and increased sensitivity to oxidative and environmental stress. Chromosome fragility induced by DNA-alkylating agents such as mitomycin-C (MMC) or diepoxybutane (DEB) is the gold standard test for FA diagnosis. These assays can further differentiate FA patients from mosaic patients. Somatic mosaicism occurs when there is a spontaneous reversion mutation that can lead to a mixed chimerism of corrected and uncorrected bone marrow cells leading to stabilization or correction of an FA patients blood counts in the absence of any administered therapy. Somatic mosaicism provides strong rationale for the development of FA gene therapy and demonstrates the selective advantage of gene-corrected hematopoietic cells in FA1.

1Soulier, J.,et al. (2005) Detection of somatic mosaicism and classification of Fanconi anemia patients by analysis of the FA/BRCA pathway. Blood 105: 1329-1336

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The companys platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients contending with rare genetic diseases. Rocket's clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD) a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. Rockets first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. Rockets pre-clinical pipeline program is for Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. For more information about Rocket, please visit http://www.rocketpharma.com.

Rocket Cautionary Statement Regarding Forward-Looking Statements

Various statements in this release concerning Rocket's future expectations, plans and prospects, including without limitation, Rocket's expectations regarding the safety, effectiveness and timing of product candidates that Rocket may develop, to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Infantile Malignant Osteopetrosis (IMO) and Danon disease, and the safety, effectiveness and timing of related pre-clinical studies and clinical trials, may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as "believe," "expect," "anticipate," "intend," "plan," "will give," "estimate," "seek," "will," "may," "suggest" or similar terms, variations of such terms or the negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket's ability to successfully demonstrate the efficacy and safety of such products and pre-clinical studies and clinical trials, its gene therapy programs, the pre-clinical and clinical results for its product candidates, which may not support further development and marketing approval, the potential advantages of Rocket's product candidates, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, Rocket's and its licensors ability to obtain, maintain and protect its and their respective intellectual property, the timing, cost or other aspects of a potential commercial launch of Rocket's product candidates, Rocket's ability to manage operating expenses, Rocket's ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives, Rocket's dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled "Risk Factors" in Rocket's Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, filed November 8, 2019. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191206005080/en/

Here is the original post:
Rocket Pharmaceuticals Announces First Patient Treated in Global Registrational Phase 2 Study of RP-L102 Process B for Fanconi Anemia - BioSpace

Brave new world? Why the public might be ready for gene-edited babies – Genetic Literacy Project

Should we be able to genetically design our children before they are born giving them the eye and hair color we prefer, deciding their sex and height, and even genetically manipulating their intelligence? Most, including top scientists and genetic counselors, say no. But what if the genetic manipulation was done in order to cure a debilitating or potentially fatal illness before the individual was even born? And what if this one genetic treatment could save the individuals descendants from inheriting the disorder, too? A 2018 meeting of non-scientists in Germany indicated that public opinion may be moving in the yes direction.

Though gene editing technology isnt yet at the point where we can genetically alter unborn individuals at the clinical level by applying gene editing tools like CRISPR/Cas9 to embryos, sperm or egg cells the technology is rapidly advancing.

Debate over the subject was rekindled last year, when a Chinese researcher announced that he used CRISPR to create the worlds first gene-edited babies. According to the Associated Press, He Jiankui said he altered embryos for seven couples during fertility treatments. The treatment was designed to protect the children of an HIV-positive parent by disabling a gene that would have allowed the virus to enter their cells. The trial resulted in one pregnancy twins who were born in November. According to the Associated Press, the researcher said:

I feel a strong responsibility that its not just to make a first, but also make it an example. Society will decide what to do next.

The gene-editing community has grappled with the unexpected announcement in the following months. It was not well received by other researchers, with many of them condemning the action. Feng Zhang, one of the inventors of CRISPR, called for an moratorium on gene-edited babies. Zhang wrote:

Not only do I see this as risky, but I am also deeply concerned about the lack of transparency surrounding this trial. All medical advances, gene editing or otherwise and particularly those that impact vulnerable populations, should be cautiously and thoughtfully tested, discussed openly with patients, physicians, scientists, and other community members, and implemented in an equitable way.

Its not unusual to see articles and reports in the media focusing on the worst possible scenarios when it comes to genome editing, as is often the case with new or particularly disruptive technologies. The mere mention of the topic tends to incite fears of a New Eugenics master race or exacerbation of medical inequalities along class lines where the poor are barred from genetic interventions and the rich have easy access. Still others, such as some Catholic and Muslim groups, worry that genetic manipulation of any sort is interfering with divine plans.

These kinds of fears have been gradually loosening their hold on our imaginations, while the coolly-measured possibilities of gene editing nothing more than a new and innovative medical tool are winning over. And as with any new technology, it comes with a particular set of risks and benefits that must be taken into consideration. The slow change in public attitude toward gene editing is evident in groups such as Germanys Citizens Delphi Germline Therapy project at Karlsruhe Institute of Technology (KIT).

After debating detailed information on the risks and benefits over the course of a few months, and undergoing a rigorous participation process that combined aspects of Citizens Jury with the Delphi survey method, the group has called for the loosening of bans on germline gene editing research in Germany. Their final report was presented at Berlin Science Week in late 2018. And though their verdict only applies to the current ban in Germany, which includes a ban on basic research in germline cells, the groups decision could have an impact on regulations around the world. Indeed, the participants were keen on having Germany play a more active role in the development of international gene editing guidelines.

Regarding the Citizens Jury and Delphi survey methods used, Ralf Grtker, who developed and carried out the project in collaboration with the Department of Science Communication at the Institute for German Studies at KIT, stated, The process is geared towards working on a complex topic with a group of laypeople, empower them to make an informed judgment, and eventually reach recommendations for politicians. Though the group only consisted of 26 German citizens, the group was representative of the population, and the topic of gene editing was thoroughly investigated from a variety of angles.

The group acknowledged the risks of genome editing, such as unknown and off-target effects, but ultimately agreed that the way forward was to open the doors to germline gene editing research at the national and global levels. Their conclusions also echoed those made by genetics experts in a position statement published in the August 2017 issue of the American Journal of Human Genetics, which stated, At this time, given the nature and number of unanswered scientific, ethical, and policy questions, it is inappropriate to perform germline gene editing that culminates in human pregnancy.

But to answer those scientific, ethical, and policy questions, basic research is crucial. And lines of communication need to be open between countries, and between scientists and non-scientists. Without these measures, misunderstandings and missed clinical opportunities will proliferate, along with the dangers of underground gene editing and gene editing tourism. Several governments around the world are grappling with heated and unresolved debates regarding germline gene editing, which in several cases appear to be impeding research.

Though a great deal of cooperation and knowledge exchange is taking place between countries, other nations have yet to move away from all-out bans on germline gene editing. Canada, for example, has criminalized germline gene editing under the 2004 Assisted Human Reproduction Act. Penalties for the crime of germline gene tampering include a $500,000 CAD fine and up to 10 years of jail time.

Following a presentation at the annual Till & McCulloch Meetings of stem-cell and regenerative-medicine researchers, Bartha Knoppers, a health policy expert at McGill University in Montreal, said, Canadas policy has simply shut down discussion (about gene editing). We need to start to talk. Some Canadian scientists worry that Canada is lagging behind in gene editing research, unable to fully participate in the global conversation taking place on this important subject.

At the other end of the spectrum are countries like Japan, where a proposal allowing for the use of gene editing tools in human embryos has been drafted. The new guidelines would restrict manipulation of human embryos for reproduction, though this restriction would likely not be legally binding.

Though several countries have formal bans in place restricting germline gene editing, many of these same countries allow for somatic (or non-reproductive) gene editing applications, which is when gene editing tools are applied to adult cells. Somatic gene edits are not passed on to future generations, so there is less concern about the possible repercussions.

A version of this article previously ran on the GLP on Nov 27, 2018.

Kristen Hovet covers genetics, medical innovations, and the intersection of sociology and culture. Follow her on her website or Twitter @kristenhovet

Here is the original post:
Brave new world? Why the public might be ready for gene-edited babies - Genetic Literacy Project

Must-Reads Of The Week From Brianna Labuskes – Kaiser Health News

Happy Friday! Hope everyone had a lovely, restful Thanksgiving. And heres your periodic (and Im sure very appreciated and not at all tiresome) reminder not to be one of the nearly 40% of Americans who plan to skip their flu shot.

Now on to our jam-packed week of news! Heres what you might have missed.

There seems to be some conflicting narrative around what exactly a new health care spending analysis means, but one thing is clear: We are now spending $11,172 per person and that is uh a lot, to say the least. Spending on health care grew at a slower pace than the economy overall. But the spending didnt increase because people were going to the doctor more. Instead, price hikes made up for the slower usage growth found by the HHS analysis.

If you want a good plain-English breakdown of what this means, check out this Axios summary of it all; they do a better job than I could. (No one told me thered be math!) Or listen to KHNs What The Health podcast by our fabulously knowledgeable Julie Rovner.

The New York Times: Health Spending Grew Modestly, New Analysis Finds

Axios: Health care spending grew at a faster rate in 2018

KHN: What The Health?: We Spend HOW MUCH On Health Care?

Speaking of outrageous hospital prices, in a move that shocked no one, hospitals officially filed a suit against the Trump administration rule that would compel them to share secretly negotiated prices for procedures.

The New York Times: Hospitals Sue Trump to Keep Negotiated Prices Secret

There has been an absolute flood of news out of the Trump administration this week, so buckle up.

Nearly 700,000 Americans are slated to lose their food stamp benefits under a new rule that tightens the work requirements in the Supplemental Nutrition Assistance Program (commonly known as SNAP). The move will purportedly save the government $5.5 billion over five years. The Agriculture Department defended the decision to crack down on waivers that extend the time a beneficiary can receive aid as, essentially, if not now (when the economy is good), then when?

Critics were quick to point out the economic and moral pitfalls of this kind of decision, among them being: Most beneficiaries work, and many of the ones who dont usually have a reason beyond wanting the $1.83 per meal that they receive under SNAP; its been shown that SNAP spending helps cushion the economy during a recession; and the people being cut off are among the most vulnerable in our society.

The Associated Press: 668,000 will lose food stamp benefits under new work rules

As part of the administrations goal to eradicate the HIV epidemic, HHS announced that uninsured Americans can now get free HIV-prevention drugs. While PrEP has been shown to be wildly successful, many people who are at high risk of contracting the virus arent taking the drug for one reason or another.

(I wonder if this is all a bit awkward, considering that HHS and PrEPs maker are locked in a bitter patent battle.)

The New York Times: 200,000 Uninsured Americans to Get Free H.I.V.-Prevention Drugs

Attorney General William Barr made waves when he suggested that communities upset with police brutality might lose protections from the cops theyre protesting. The remarks which seemed to encourage abandonment as a form of retribution for those seeking criminal justice reform were quickly condemned as dangerous.

The New York Times: Barr Says Communities That Protest the Police Risk Losing Protection

A new investigation from Reuters found that the FDA ignored warning bells about the dangers of talc as early as the 1970s. The agency for decades deferred to the industry over outside experts advice.

Reuters: FDA bowed to industry for decades as alarms were sounded over talc

And a disturbing video obtained by ProPublica contradicts the Border Patrols account of the death of a sick 16-year-old who was being held in U.S. custody. The video shows the boy staggering to the toilet and collapsing on the floor, where he remained in the same position for the next four-and-a-half hours. According to ProPublica, The video shows the only way CBP officials could have missed Carlos crisis is that they werent looking. Border Patrol also said it was agents who found his body but in reality a cellmate alerted them to his death.

ProPublica: Inside the Cell Where a Sick 16-Year-Old Boy Died in Border Patrol Care

Meanwhile, new documents reveal how a powerhouse consulting firm proposed money-saving methods for the detention centers that included proposed cuts in spending on food for migrants, as well as on medical care and supervision of detainees.

ProPublica: How McKinsey Helped the Trump Administration Detain and Deport Immigrants

Over on the presidential campaign trail, Medicare for All continues to trip up the candidates, including Sen. Elizabeth Warren (D-Mass.), whose fate seems to have become tied to the proposal, which wasnt even hers to start with. Politico takes us all the way back to a town hall in 2017 hosted by Sen. Kamala Harris (D-Calif.) to figure out how we got to where we are today.

Politico: The most consequential moment of the 2020 primary

The Washington Post: How a fight over health care entangled Elizabeth Warren and reshaped the Democratic presidential race

Meanwhile, some Dems in the race are touting a public option as a moderate alternative to Medicare for All, but dont let that fool you. That kind of shift could still send an earthquake through the health care landscape.

The New York Times: Why the Less Disruptive Health Care Option Could Be Plenty Disruptive

Gains made by the anti-abortion movement in recent years are often attributed to a well-executed ground game by the right. But there have also been crucial missteps on the other side of the abortion wars. Critics say that the national abortion rights movement lost touch with the ways access was steadily eroding in Republican strongholds, and that leaders grew overconfident during Barack Obamas presidency. As one director of a clinic in Atlanta told The New York Times: We were screaming at the top of our lungs, everything is not fine, please pay attention.

The New York Times: How a Divided Left Is Losing the Battle on Abortion

Theres been a ton of buzz around the first major gun case the Supreme Court took up in nearly a decade. But will it all be for naught? Arguments in the case, which centers around a NYC handgun ordinance, focused on the fact that the city got rid of the contested limits in July.

Reuters: U.S. Supreme Court justices debate whether to dismiss major gun case

I have to say I did not expect to read the phrase we are feared as a tiger with claws, teeth and balls when I kicked off my workweek, but here we are. As seems to be the case every time we get unsealed documents dealing with the Sackler family, the newest ones reveal how deeply involved Richard Sackler was in the aggressive push to market OxyContin.

Stat: Purdues Richard Sackler proposed plan to play down OxyContin risks, and wanted drug maker feared like a tiger, files show

So often opioid news focuses on the big players and court cases these days. But in this article, people who were high school kids at the time the epidemic was really starting to brew talk about how their lives have been irrevocably changed by the crisis.

The New York Times: The Class of 2000 Could Have Been Anything. Until Opioids Hit.

Despite the fact that it seems warnings are everywhere about the dangers of vaping, a new survey reveals that nearly 1 in 3 teens have used a tobacco product recently. Whats more, many students said they did not consider intermittent smoking of any product to be harmful.

The New York Times: Nearly a Third of Teens Use One or More Tobacco Products

In the miscellaneous file for the week:

In Rhode Island, 11 patients over a two-and-a-half-year span died because of a misplaced breathing tube (something thats never supposed to happen in emergency medicine). The state is the only one in New England to allow responders other than the most highly trained paramedics to place the tubes. But advocates say that, if they tighten those rules, it will cost even more lives, because fewer patients will have access to the equipment.

ProPublica: EMS Crews Brought Patients to the Hospital With Misplaced Breathing Tubes. None of Them Survived.

Every once in a while were hit with a story that reminds us that relying on technology especially when it comes to health care is a dangerous game despite the benefits it brings. This time it was a glitch with diabetes monitors.

Stat: A glitch in diabetes monitors serves as a cautionary tale for health tech

Patients who are desperate for a miracle are being given tips by stem cell clinics on how to raise enough money to afford unproven, and sometimes dangerous, treatments. Theres always GoFundMe, the clinics say when met with the patients financial barriers.

The Washington Post: Clinic pitches unproven treatments to desperate patients, with tips on raising the cash

Thats it from me! Have a great weekend.

Read the original here:
Must-Reads Of The Week From Brianna Labuskes - Kaiser Health News

Brenner and Rector’s The Kidney, 2-Volume Set. Edition No. 11 – ResearchAndMarkets.com – Associated Press

DUBLIN--(BUSINESS WIRE)--Dec 6, 2019--

The Brenner and Rectors The Kidney, 2-Volume Set. Edition No. 11 book has been added to ResearchAndMarkets.coms offering.

Put the worlds most well-known kidney reference to work in your practice with the 11th Edition of Brenner & Rectors The Kidney. This two-volume masterwork provides expert, well-illustrated information on everything from basic science and pathophysiology to clinical best practices. Addressing current issues such as new therapies for cardiorenal syndrome, the increased importance of supportive or palliative care in advanced chronic kidney disease, increasing live kidney donation in transplants, and emerging discoveries in stem cell and kidney regeneration, this revised edition prepares you for any clinical challenge you may encounter.

Key Topics Covered:

1. Embryology of the Kidney

2. Anatomy of the Kidney

3. The Renal Circulations and Glomerular Ultrafiltration

4. Glomerular Cell Biology

5. Metabolic Basis of Solute Transport

6. Transport of Sodium, Chloride, and Potassium

7. The Regulation of Calcium, Magnesium, and Phosphate Excretion by the Kidney

8. Renal Handling of Organic Solutes

9. Renal Acidification Mechanisms

10. Urine Concentration and Dilution and The Cell Biology of Vasopressin Action

11. Vasoactive Molecules and the Kidney

12. Aldosterone and Mineralocorticoid Receptors: Renal and Extrarenal Roles

13. Arachidonic Acid Metabolites and the Kidney

14. Disorders of Sodium Balance

15. Disorders of Water Balance

16. Disorders of Acid-Base Balance

17. Disorders of Potassium Balance

18. Disorders of Calcium, Magnesium, and Phosphate Balance

19. Epidemiology of Kidney Disease

20. Risk Prediction in Chronic Kidney Disease

21. Developmental Programming of Blood Pressure and Renal Function

22. Physiology and Pathophysiology of the Aging Kidney

23. Clinical Approach and Laboratory Assessment of the patient with kidney disease

24. Interpretation of Electrolyte and Acid-Base Parameters in Blood and Urine

25. Diagnostic Kidney Imaging

26. The Kidney Biopsy

27. Biomarkers in Acute and Chronic Kidney Diseases

28. Pathophysiology of Acute Kidney Injury

29. Prevention and Management of Acute Kidney Injury

30. Pathophysiology of Proteinuria

31. Primary Glomerular Disease

32. Secondary Glomerular Disease

33. Overview of Therapy for Glomerular Disease

34. Thrombotic Microangiopathy and Microvascular Disease

35. Tubulointerstitial Diseases

36. Urinary Tract Infection in Adults

37. Urinary Tract Obstruction

38. Urinary Stone Disease

39. Diabetic Nephropathy

40. Cardiorenal Syndromes

41. Kidney Cancer

42. Onco-Nephrology: Kidney Disease in Patients with Cancer

43. Inherited Disorders of the Glomerulus

44. Inherited Disorders of the Renal Tubule

45. Cystic Diseases of the Kidney

46. Primary and Secondary Hypertension

47. Renovascular Hypertension and Ischemic Nephropathy

48. Pregnancy and Kidney Disease

49. Antihypertensive Therapy

50. Diuretics

51. Mechanisms of Progression of Chronic Kidney Disease

52. The Pathophysiology of Uremia

53. Chronic Kidney Disease-Mineral Bone Disorder

54. Cardiovascular Aspects of Kidney Disease

55. Hematologic Aspects of Kidney Disease

56. Endocrine Aspects of Chronic Kidney Disease

57. Neurologic Aspects of Kidney Disease

58. Dermatologic Conditions in Kidney Disease

59. Staging and Management of Chronic Kidney Disease

60. Dietary Approaches to Kidney Diseases

61. Drug Dosing Considerations in Patients with Acute Kidney Injury and Chronic Kidney Disease

62. Supportive Care in Advanced Kidney Disease

63. Hemodialysis

64. Peritoneal Dialysis

65. Critical Care Nephrology

66. Plasmapheresis

67. Elimination Enhancement of Poisons

68. Interventional Nephrology

69. Transplantation Immunobiology

70. Clinical Management of the Adult Kidney Transplant Recipient

71. Considerations in Live Kidney Donation

72. Diseases of the Kidney and Urinary Tract in Children

73. Fluid, Electrolyte, and Acid-Base Disorders in Children

74. Renal Replacement Therapy (Dialysis and Transplantation) in Pediatric End-Stage Kidney Disease

75. Global Challenges and Initiatives in Kidney Health

76. Latin America

77. Africa

78. Near and Middle East

79. Indian Subcontinent

80. Far East

81. Oceania Region

82. Ethical Dilemmas Facing Nephrology: Past, Present, and Future

83. Health Disparities in Nephrology

84. Care of the Older Adult with Chronic Kidney Disease

85. Stem Cells, Kidney Regeneration, Gene and Cell Therapy in Nephrology

Authors

Yu, Alan S. L. Harry Statland and Solon Summerfield Professor of Medicine, Director, Division of Nephrology and Hypertension and the Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas.

Chertow, Glenn M. Norman S. Coplon/ Satellite Healthcare, Professor of Medicine, Chief, Division of Nephrology, Stanford University School of Medicine, Stanford, Palo Alto, California, USA.

Luyckx, Valerie Affiliate Lecturer, Renal Division, Brigham and Womens Hospital, Harvard Medical School, Boston, MA, Institute of Biomedical Ethics and the History of Medicine

University of Zurich, Zurich, Switzerland.

Marsden, Philip A. Professor of Medicine, Elisabeth Hofmann Chair in Translational Research, Oreopoulos-Baxter Division Director of Nephrology; Vice Chair Research, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Skorecki, Karl Annie Chutick Professor and Chair in Medicine (Nephrology), Technion-Israel Institute of Technology, Director of Medical and Research Development, Rambam Health Care Campus, Haifa, Israel.

Taal, Maarten W. Professor of Medicine, Division of Medical Sciences and Graduate Entry Medicine, University of Nottingham; Honorary Consultant Nephrologist, Department of Renal Medicine, Royal Derby Hospital, Derby, United Kingdom.

For more information about this book visit https://www.researchandmarkets.com/r/klnzw8

View source version on businesswire.com:https://www.businesswire.com/news/home/20191206005135/en/

CONTACT: ResearchAndMarkets.com

Read the original here:
Brenner and Rector's The Kidney, 2-Volume Set. Edition No. 11 - ResearchAndMarkets.com - Associated Press